DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA)

CAPS Rating: 3 out of 5

A dermatology company, which is engaged in the development and marketing Levulan photodynamic therapy and other products for common skin conditions.

Recs

1
Player Avatar Turtlebale (< 20) Submitted: 3/3/2011 1:27:32 PM : Outperform Start Price: $4.18 DUSA Score: +83.90

great growth, low valuation

Featured Broker Partners


Advertisement